Stockreport

Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication

Harrow Health, Inc.  (HROW) 
Last harrow health, inc. earnings: 11/13 04:21 pm Check Earnings Report
PDF NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today annou [Read more]